A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Latest Information Update: 05 Feb 2026
At a glance
- Drugs SHR-1918 (Primary)
- Indications Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 02 Feb 2026 Status changed from not yet recruiting to recruiting.
- 20 Nov 2025 New trial record